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Materials and Methods 
Experimental protocol 
The experiment was conducted according to a single dose parallel design with each group 
containing six 9-week-old male pigs. The animals received a bolus of 6 mg/kg body weight GAM 
(Zactran®, Merial, see Fig. 1) intravenously (IV) in the ear vein (n=6) or subcutaneously (SC) in 
the flank region (n=6). Blood was collected from the jugular vein before administration (time 0), 
at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12 h post-administration (p.a.) and once daily from day 2 to 
day 14 p.a. Plasma was stored at ≤ -15°C until analysis.  
 
GAM analysis 
Quantitation of GAM in porcine plasma was carried out using an in-house developed and 
validated liquid chromatography-tandem mass spectometry (LC-MS/MS) method. The sample 
























Figure 1. Chemical structure of GAM                   
                                   
                                 Figure 2. Diagram of GAM sample preparation 
                                 steps before LC-MS/MS analysis 
 
 
PK and Statistical analysis 
The PK parameters were analysed using WinNonlin®, version 6.2.0 (Pharsight). A non-
compartmental model was used to determine the area under the plasma concentration-time 
curve from 0 to the last quantifiable time point (AUClast), the AUC extrapolated to infinity 
(AUCinf), the elimination rate constant (λz), the terminal half-life (t1/2λz, expressed as the 
harmonic mean), volume of distribution (Vss), plasma clearance (Cl), maximum plasma 
concentration (Cmax) and time to Cmax (Tmax).  
The absolute bioavailability (F) was calculated from the following equation:  
F (%) = (AUCinf SC / AUCinf IV) × 100 
The data were statistically analysed by means of single-factor analysis of variance (ANOVA), 
using PASW Statistics 20 (IBM SPSS Software). A value of P<0.05 was considered significant. 
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Introduction 
Gamithromycin (GAM), a 15-membered semi-synthetic macrolide antibiotic of the azalide subclass, has recently been developed for the treatment and prevention of bovine respiratory 
disease. Besides the anti-infectious properties, macrolides have frequently been reported to be able to influence various inflammatory processes.  
The aim of this study was to determine the pharmacokinetic (PK) parameters of gamithromycin in pigs, whereafter the disposition of the antibiotic can be used in further research to 
investigate its immunomodulating properties in a porcine lipopolysaccharide (LPS) inflammation model. 
Parameter Unit IV SC 
AUClast µg.h/mL 3.24 ± 0.56 3.48 ±1.90 
AUCinf µg.h/mL 3.67 ± 0.75 4.31 ± 1.14 
λz /h 0.043 ± 0.011 0.037 ± 0.009 
T1/2λz h 16.03
A  18.76A 
Vz L/kg 40.47 ± 8.73 42.70 ± 16.16 
Vss L/kg 31.03 ± 6.68  - 
Cl L/h.kg 1.69 ± 0.33 1.47 ± 0.40 
Tmax h  - 0.63 ± 0.21 
C0 µg/mL 1.37 ± 1.09  - 
Cmax µg/mL  - 0.41 ± 0.090 
F %  - 117.56 ± 39.36 
Results 
The semi-logarithmic plots of the plasma concentration-time curves after IV and 
SC administration are depicted in Fig. 3. 
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Discussion and Conclusion 
In pigs a higher clearance of GAM is observed compared to cattle (1.69 vs 0.71 L/h.kg), resulting 
in a shorter half-life of elimination (16.03 and 44.9 h after IV administration in pigs and cattle, 
respectively). The volume of distribution is very high (31.03 and 24.9 L/kg in pigs and cattle, 
respectively), indicating a distinct tissue penetration and intracellular levels. 
None of the pharmacokinetic parameters were significantly different between both administration   
routes. 
 
We can conclude that there is a fast and complete absorption (F = 117%), a 
distinct tissue penetration and a faster elimination compared to cattle of GAM 
following SC administration in pigs. 
 
In future research, these pharmacokinetics will be applied in  
a porcine LPS-inflammation model to investigate the individual and synergistic 
immunomodulatory properties of GAM.  The influence of GAM  
on the protein expression of pro-inflammatory cytokines,  
acute phase proteins and fever suppression will be investigated. 
Figure 3. Mean (± SD) plasma concentration-time profiles of gamithromycin 
after IV (n=6) and SC (n=6) bolus administration of 6 mg/kg BW in pigs 
Table 1. Pharmacokinetic parameters for gamithromycin in pigs after IV 
(n=6) and SC (n=6) bolus administration of 6 mg/kg BW (mean ± SD) 
  
A:harmonic mean 
